explore -WSS

explore

author：Wikipedia 2025-09-03 05:31:38 - browse：71

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Innovation in antibiotics is ailing. 'Brain drain' may kill it

WSS

Doctors find melanoma drugs effective against rare brain cancer

Listen: Wegovy in the brain & pivotal Alzheimer's data

Ultragenyx gene therapy for rare liver ailment succeeds in late

Intellia reports positive results for its CRISPR

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

In early work, researchers turn to CRISPR to treat Alzheimer's

knowledge

explore

entertainment

Continuity nursing helped my family in our darkest PICU moments

ASCO: Palliative care found as helpful given virtually as in person

Drug repurposing or repositioning? The language matters

Letters to First Opinion on caregivers, digital health, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Biden tests positive for Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

23andMe had bad news about my health. I wish a person had delivered it

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

hotspot

FDA approves RSV monoclonal antibody for infants, toddlers

Medicare has a new plan to address drug shortages

WHO calls for emergency meeting on new China virus, as cases spread

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Biden tests positive for Covid

Let's speed up science by embracing open access publishing

knowledge

focus

hotspot

hotspot